SCHEMBL5786508

SCHEMBL5786508

COC(=O)[C@H](Cc1ccc(O)c(OC)c1)NC(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK5 Q9Y337 1/20 0.52
LCK P06239 1/20 0.51
FOS P01100 1/20 0.50
TTR P02766 1/20 0.50
JUN P05412 1/20 0.50
NR3C1 P04150 1/20 0.50
HSD17B1 P14061 1/20 0.50
HSD17B2 P37059 1/20 0.50
MMP1 P03956 1/20 0.48
CYP3A4 P08684 1/20 0.48
CTSS P25774 2/20 0.47
CTSK P43235 2/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47
TACR1 P25103 1/20 0.47
ITGA4 P13612 2/20 0.46
ITGB7 P26010 2/20 0.46
ALOX5 P09917 1/20 0.46
OR51E2 Q9H255 1/20 0.46
CTSB P07858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24476991 1.00 KLK5 (0.52) KLK5LCKFOSTTRJUN
SCHEMBL14556176 0.95 ITGA4 (0.50) KLK5LCKFOSTTRJUN
SCHEMBL2352503 0.91 ITGA4 (0.56) FOSTTRJUNNR3C1HSD17B1
SCHEMBL5363804 0.91 ITGA4 (0.56) FOSTTRJUNNR3C1HSD17B1
SCHEMBL7439577 0.90 KLK5 (0.54) KLK5CTSSCTSKTACR1ITGA4
SCHEMBL15711996 0.90 KLK5 (0.49) KLK5LCKCTSSCTSKTACR1
SCHEMBL3013717 0.89 LCK (0.64) KLK5LCKCTSSCTSKCTSB
SCHEMBL3013721 0.89 LCK (0.64) KLK5LCKCTSSCTSKCTSB
SCHEMBL5375331 0.88 TACR1 (0.53) KLK5CTSSCTSKTACR1ITGA4
SCHEMBL10042354 0.88 KLK5 (0.52) KLK5LCKCTSSCTSKTACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1049662-B1 INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION TANABE SEIYAKU CO (JP) 2006-06-21 EP disclosed
US-6855843-B2 Inhibitors of α4 mediated cell adhesion TANABE SEIYAKU CO., LTD. (JP) 2005-02-15 US disclosed
US-20030191118-A1 Inhibitors of alpha4 mediated cell adhesion TANABE SEIYAKU CO., LTD. 2003-10-09 US disclosed
US-6521666-B1 Inhibitors of α4 mediated cell adhesion TANABE SEIYAKU CO., LTD. (JP) 2003-02-18 US disclosed
EP-1049662-A1 INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 2000-11-08 EP disclosed
WO-1999036393-A1 INHIBITORS OF α4 MEDIATED CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 1999-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191118-A1 Inhibitors of alpha4 mediated cell adhesion ITGB4, ITGA4, VCAM1 KLK5 4414/4885LCK 3162/4885FOS 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.